RT Journal Article
SR Electronic
T1 Anemia during pregnancy and adverse maternal outcomes in Georgia – a birth registry-based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.10.23298382
DO 10.1101/2023.11.10.23298382
A1 Skhvitaridze, Natia
A1 Gamkrelidze, Amiran
A1 Manjavidze, Tinatin
A1 Brenn, Tormod
A1 Anda, Erik
A1 Rylander, Charlotta
YR 2023
UL http://medrxiv.org/content/early/2023/11/11/2023.11.10.23298382.abstract
AB Background Anemia in pregnancy is an important public health challenge; however, it has not been thoroughly studied in Georgia. We assessed the prevalence of anemia during pregnancy across Georgia and the association between anemia in the third trimester of pregnancy and adverse maternal outcomes.Methods We used data from the Georgian Birth Registry and included pregnant women who delivered between January 1, 2019, and August 31, 2022 (n=158,668). The prevalence of anemia (hemoglobin (Hb) < 110 g/L) at any time during pregnancy was calculated per region. Women in the third trimester were classified into three groups, based on their lowest measured Hb value: no (Hb ≥110 g/L, reference group); mild (Hb 100-109 g/L); and moderate to severe anemia (Hb <99 g/L). Adjusted odds ratios (aOR) with 95% confidence intervals (CIs) were calculated for the associations between anemia status and post-delivery intensive care unit (ICU) admission and preterm delivery.Results The prevalence of anemia occurring at least once during pregnancy was 40.6%, with large regional differences in anemia prevalence (25.1%–47.0%). Of 105,811 pregnant women with Hb measurements in the third trimester, 71.0% had no anemia; 20.9%, mild anemia; and 8.1%, moderate or severe anemia. The odds of post-delivery ICU admission did not increase linearly with decreasing Hb value (P for trend .13), and the relationship was inverse for preterm delivery (P for trend .01).Conclusions A considerable proportion of pregnant women in Georgia have anemia during pregnancy, and the prevalence and quality of reporting differ across regions. Anemia occurring in the third trimester did not substantially increase the odds of maternal ICU admission or preterm delivery. To accelerate national progress toward the Sustainable Development Goals and mitigate the consequences of anemia, equal countrywide access to high-quality antenatal care programs and complete registration of Hb values should be ensured.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of National Center for Disease Control and Public Health approved the legal aspects of this study (IRB #2023-001). In addition, Regional Committees for Medical and Health Research Ethics in Northern Norway approved the study protocol (Ref: 577179, 20/02/2023). All data included in this study were extracted from the GBR and anonymized before the researchers received the data. Registration in the national registries is mandatory by law, and citizens cannot refuse registration. Consent was not obtained from the study participants as it is deemed unnecessary according to national regulations. The study reporting is in line with the Helsinki declaration and the strengthening the reporting of observational studies in epidemiology (STROBE) guideline.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccording to Georgian legislation, data from central health registries can be used for research purposes as long as personal data is not shared. Data collected for this study are not publicly available because they contain personalized and potentially identifying information. Proper ethical and legal approvals are required for access before requesting the data, and only anonymous/pseudonymized data can be shared. Researchers can contact the National Center for Disease Control and Public Health in Georgia (ncdc{at}ncdc.ge) or the corresponding author (natia.skhvitaridze{at}uit.no) for assistance on how to apply for access to data from registry.